The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...

The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...

Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...

The U.S. FDA ordered a pause on clinical trials of a combination therapy for HIV. This won't affect the company's other HIV ...

Trump administration officials are expected to release more details on their plan to lower prescription drug prices in the ...

Gilead Sciences Inc. said federal regulators had placed on hold trials of a new experimental once-weekly HIV drug combination therapy after white blood cell counts dropped in some of the patients ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

After years of stagnation, Gilead is betting that a twice-yearly HIV shot can restart its growth engine.

The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...